Logo

Qiagen QuantiFeron SARS-CoV-2 RUO Assay

Dec 07, 2020

Qiagen has launched the QuantiFeron SARS-CoV-2 RUO assay to detect T-cell responses of the human immune system to the SARS-CoV-2 virus. The assay, which is for research use only, could help researchers gain new information on immunity levels and disease progression. Studies have suggested that T cell response to the virus declines much more slowly than antibody response, and that it provides a reliable indication of how severe the course of illness will be in infected patients.

The new product will initially comprise a 'starter set' and a 'monitor direct' package for separate or combined research use. Both are made up of QuantiFeron blood collection tubes with a proprietary stimulation principle, and the QuantiFeron detection system to measure the resulting interferon-gamma.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.